• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

FDA Clears Deep Learning Image Reconstruction for Spotlight CT Scanners

News
Article

The artificial intelligence (AI)-powered technology reportedly offers decreased noise magnitude while enhancing image reconstruction for cardiovascular computed tomography (CT) scanners.

The Food and Drug Adminstration (FDA) has granted 510(k) clearance for the addition of deep learning image reconstruction (DLIR) to the Spotlight™ cardiovascular computed tomography (CT) and Spotlight Duo cardiothoracic CT systems.

Utilizing an advanced convolutional neural network (CNN), the DLIR technology maintains high-contrast spatial resolution while reducing pixel-wise noise magnitude, according to Arineta Cardio Imaging, the manufacturer of the aforementioned CT systems.

Trained on more than three billion image data points, the DLIR technology enhances the use of cross-sectional images for cardiovascular imaging assessment in a variety of settings.

“We have used Arineta cardiac CT systems for several years, and they provide the highest quality cardiac CT clinical images for our practice. From our FDA 510(k) reader study, Arineta’s DLIR technology continues that excellence. Arineta’s SpotLight systems make the highest performance cardiac CT available at point-of-care, in an office, mobile, or cath lab setting,” said Matthew Budoff, M.D., the director of Cardiac Computed Tomography within the Division of Cardiology at the Harbor-UCLA Medical Center in Torrance, Ca.

Recent Videos
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Related Content
© 2024 MJH Life Sciences

All rights reserved.